As of June 14, 2025, Biodesix Inc (BDSX) reports a Net Margin of -60.19%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Biodesix Inc's Net Margin
Over recent years, Biodesix Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -60.19% |
| 2023-12-31 | -106.23% |
| 2022-12-31 | -171.29% |
| 2021-12-31 | -79.18% |
| 2020-12-31 | -68.81% |
This slight upward trend highlights how Biodesix Inc manages its overall profitability and cost control over time.
Comparing Biodesix Inc's Net Margin to Peers
To better understand Biodesix Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Biodesix Inc (BDSX) | -60.19% |
| Global Cord Blood Corp (CO) | 40.30% |
| Avem Health Partners Inc (FPCG) | 29.77% |
| PharmChem Inc (PCHM) | 22.69% |
| Interpace Biosciences Inc (IDXG) | 14.28% |
| Quest Diagnostics Inc (DGX) | 8.82% |
Compared to its competitors, Biodesix Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.